Latest Avastin Stories
SAN DIEGO, May 20, 2013 /PRNewswire/ -- TRACON Pharmaceuticals, a biopharmaceutical company that develops targeted therapies for oncology and ophthalmology, today announced multiple clinical investigations for TRC105 and the presentation of two abstracts at the 49(th) Annual Meeting of the American Society of Clinical Oncology (ASCO), held May 31 to June 4 in Chicago. TRC105, a novel monoclonal antibody to endoglin (CD105), is being studied in multiple clinical trials in combination...
Dr. Stephen Keefe to present clinical data demonstrating CRLX101's combinability with Avastin® to treat renal cell carcinoma CAMBRIDGE, Mass., April 4, 2013 /PRNewswire/ -- Cerulean Pharma Inc., a leader in dynamically tumor-targeted nanopharmaceuticals, today announced that researchers will present both pre-clinical and clinical data on Cerulean's Phase 2 candidate, CRLX101, in sessions at the American Association for Cancer Research (AACR) Annual Meeting. Among the findings,...
VANCOUVER, British Columbia, Nov. 15, 2012 /PRNewswire/ -- Del Mar Pharmaceuticals (BC) Ltd. ("DelMar Pharma") today announced that the Company will present two scientific posters at the Society for Neuro-Oncology (SNO) 17(th) Annual Scientific Meeting, which is being held in Washington, DC November 15-18, 2012. On Friday November 16(th), DelMar will present a poster entitled, "VAL-083, Novel N7 Alkylating Agent, Surpasses Temozolomide Activity and Inhibits Cancer Stem Cells...
CAMBRIDGE, Mass., July 2, 2012 /PRNewswire/ -- Cerulean Pharma Inc., a leader in developing dynamically tumor-targeted nanopharmaceuticals, today announced that the first patient has been dosed in a Phase 1b/2a study of its lead product candidate, CRLX101, in combination with Avastin®, in metastatic renal cell carcinoma (mRCC) patients. The company also announced the completion of enrollment of its randomized Phase 2 study in advanced non-small cell lung cancer. (Logo:...
KINGSTON, ON, June 18, 2012 /PRNewswire/ - At the center of the debate of how to potentially save the healthcare system millions of dollars are two drugs used to treat wet age-related macular degeneration (AMD), the leading cause of blindness in seniors. One, Lucentis, is FDA and Health Canada-approved and costs $1,700. The other, Avastin, is used off-label and costs one-tenth the price. Eye doctors currently use both drugs to treat AMD and some studies have shown that they are...
INCLINE VILLAGE, Nev., June 13, 2012 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced royalty revenue guidance for the second quarter ending June 30, 2012, of approximately $125 million, as compared with actual royalty revenue of $122 million for the second quarter of 2011, a two percent increase. (Logo: http://photos.prnewswire.com/prnh/20110822/SF55808LOGO) The forecasted growth in royalty revenues is driven by increased first quarter 2012 sales of...
Study shows Avastin has similar effect to Lucentis in treating most common cause of blindness in the developed world The one year results from a study into whether two drug treatments (Lucentis and Avastin), are equally effective in treating neovascular or wet age-related macular degeneration (wet AMD), have been reported today at an international research meeting in Fort Lauderdale, Florida. Wet AMD is a common cause of loss of vision in older people. In the UK, around 70 per cent of...
American Health Assistance Foundation Calls for Greater Investment in Research to Halt Eye Disease This week, the second-year results of an important clinical trial on age-related macular degeneration (AMD), known as the Comparison of AMD Treatments Trials (or CATT), were published in the journal Ophthalmology. Researchers found that two drugs known as Avastin (bevacizumab) and Lucentis (ranibizumab), commonly used to treat the wet form of AMD, were similarly effective in maintaining...
Year 2 results corroborate initial findings that 2 medications provide strikingly similar results Two drugs commonly used to treat age-related macular degeneration (AMD) yield similar improvements in vision for patients receiving treatments on a monthly or as-needed basis, according to a study from researchers at the Center for Preventive Ophthalmology and Biostatistics (CPOB) at the Perelman School of Medicine at the University of Pennsylvania. The year-two results of the Comparison of...
At two years, Avastin (bevacizumab) and Lucentis (ranibizumab injection), two widely used drugs to treat age-related macular degeneration (AMD), improve vision when administered monthly or on an as needed basis, although greater improvements in vision were seen with monthly administration for this common, debilitating eye disease, according to researchers supported by the National Institutes of Health. Of the two drugs, Avastin is most frequently used to treat AMD. However, prior to the...
